DPP4 and diabetes mellitus: These genes can be targeted by 37 medications including several antidiabetic ‘gliptins’ (dipeptidyl peptidase-4 inhibitors), which have observational evidence of a potential anti-arrhythmic role in treated patients with diabetes (Supplementary Fig. 6)21.